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Edited by Judit OvadiAbstract The serpin gene Spn4 from Drosophila melanogaster
encodes multiple isoforms with alternative reactive site loops
(RSL). Here, we show that isoform Spn4A inhibits human furin
with an apparent kassoc of 5.5 106 M1 s1. The serpin forms
SDS-stable complexes with the enzyme and the RSL of Spn4A is
cleaved C-terminally to the sequence –Arg–Arg–Lys–Arg# in
accord with the recognition/cleavage site of furin. Immunoﬂuo-
rescence studies show that Spn4A is localized in the endoplasmic
reticulum (ER), suggesting that the inhibitor is an interesting
tool for investigating the cellular mechanisms regulating furin
and for the design of agents controlling prohormone convertases.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Proteolytic events play a central role in development, innate
immune response and other important aspects in the life cycle
of Drosophila [1,2]. These proteolytic processes must be strin-
gently regulated in order to maintain homeostasis. Part of this
task is fulﬁlled by a class of protease inhibitors – the serpins –
most of which act as suicide inhibitors that present their re-
active site loop (RSL) to the catalytic cleft of target enzymes
[3].
The Drosophila melanogaster genome encodes about 30
serpin genes [4], including Spn4 (synonym: Sp4) [5]. At least
ten diﬀerent transcripts can be generated from this gene that
may encode up to eight inhibitor variants [6]. Among these,
isoform Spn4A attracted special attention due to speciﬁc se-
quence features. First, the presence of a putative N-terminal
signal peptide in combination with a C-terminal –His–Asp–
Glu–Leu (HDEL) sequence that may function as endoplas-
mic reticulum (ER) retrieval signal suggests that the protein
can cycle between the ER and the secretory routes of the cell.
Second, the RSL of Spn4A is dominated by a sequence of
basic amino acids preceding the putative scissile bond that
resembles the recognition/cleavage site of furin [7,8], a sub-
tilase-like enzyme that plays an eminent role in the activation* Corresponding author. Fax: +49-521-106-6328.
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Abbreviations: a1-PDX, a1-antitrypsin Portland; ER, endoplasmic
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stoichiometry of inhibition; TEV, tobacco etch virus
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creted proteins and peptides [9,10]. Mature mammalian furin
localizes predominantly to post-ER compartments and can
cycle between the trans-Golgi network and the cell surface
[11,12]. The involvement of furin and related proteinases in
many important events and diseases has evoked vivid interest
in the development of inhibitors and the processes regulating
these enzymes. The recently published crystal structure of
catalytic and P-domain of mouse furin complexed with deca-
noyl–Arg–Val–Lys–Arg–chloromethylketone (dec–RVKR–
cmk) [13] has paved the way for the design of eﬀective
inhibitors. Peptidyl chloroalkylketones [14] and an engineered
serpin, a1-antitrypsin Portland (a1-PDX) [15,16], have been
shown to block the furin-dependent processing of envelope
glycoproteins of pathogenic viruses, however, the cellular
mechanisms controlling the activity of furin are largely
unknown.2. Materials and methods
2.1. Materials
Plasmid pcDNA3.1+, vector pCR4-TOPO and His-tagged TEV
protease (10 units/ll) were from Invitrogen. Glutathione Sepharose
4B, LMW and HMW size marker kits for SDS–PAGE (#17-0446 and
#17-0615, respectively) were obtained from Amersham Biosciences.
Recombinant human furin (2 units/ll, corresponding to a 22 nM so-
lution of active site titratable material, see Section 2.6) was from NEB.
Protino Ni 2000 columns were from Macherey Nagel. L-pyrogluta-
myl–Arg–Thr–Lys–Arg–7-amido-4-methylcoumarin (pERTKR-MCA)
and dec–RVKR–cmk [17] were from Bachem Biochemika. The mono-
clonal antibody MON-148 [18] against human furin was from Alexis
Biochemicals. Rabbit antibodies directed against a puriﬁed GST-Spn4
fusion variant were obtained from Pineda Antik€orper Service, Berlin.
2.2. Plasmid constructions
A plasmid coding for a chimeric protein consisting of an N-terminal
His-tag, glutathione S-transferase (GST), a TEV protease cleavage site
and Spn4A was constructed as follows: An Spn4A cDNA fragment [6]
coding for amino acids 33–424 was ampliﬁed by PCR using the primers
50-GGTTCCGCGTGGATCCATGGCTGACGCCGCCCACCA (sense)
and 50-CCCGGGAATTCTCACAGCTCATCATGCTCGCTGGAG
(antisense), thus generating a cDNA ﬂanked by NcoI and EcoRI sites.
After cloning (TOPO cloning kit for sequencing, Invitrogen), an in-
ternal Spn4A NcoI site was replaced by synonymous substitutions
(QuikChange site-directed mutagenesis kit, Stratagene instruction
manual). The modiﬁed cDNA was digested with NcoI and EcoRI and
ligated into the NcoI/EcoRI cleaved vector pKM263 [19], resulting in
the expression plasmid pGST-Spn4A-1.
For expression in COS-7 cells, an Spn4A cDNA ﬂanked by KpnI and
EcoRI sites and coding for amino acids 1–424 was subcloned into
pcDNA3.1+ cleaved with KpnI and EcoRI. To this end, total RNA
from Drosophila melanogaster Schneider S2 cells [20] was reverse
transcribed and ampliﬁed using the primer 50-CGTTTAGGTAC-
CAGTATGGATTATCGTTTGGTGCCATGTGG and the antisenseblished by Elsevier B.V. All rights reserved.
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the previously published Spn4A coding region [6] with the exception of
the S2 cell-speciﬁc Gly!Val substitution at position 17 in the hy-
drophobic core of the signal peptide.2.3. Expression and puriﬁcation of Spn4A-1
Plasmid pGST-Spn4A-1 was transformed into Escherichia coli BL21.
Following incubation at 37 C to an A600 of 0.7–1.0 in LB medium
(200 ml), isopropyl -D-thiogalactopyranoside (0.1 mM) was added.
After 3–4 h at 27 C, cells were harvested, washed and stored at
)20 C. Cells were resuspended in 3.5 ml cold PBS containing 0.5%
Triton X-100, 2.5 mM EDTA, 1 mM PMSF, and 75 ll protease in-
hibitor cocktail (P8849, Sigma) and disrupted by two French press
passages (20 000 psi). Following centrifugation (40 min, 8000 g at 4
C), the soluble fraction was batch adsorbed to Glutathione Sepha-
rose 4B. After washing with PBS, 0.5% Triton X-100, followed by 50
mM HEPES, pH 7.5, the fusion protein was eluted with 50 mM
HEPES, pH 8.0, containing 10 mM reduced glutathione and stored at
)80 C.
For cleavage with TEV protease, puriﬁed GST-Spn4A-1 (0.5 mg)
was incubated for 16 h in 50 mM HEPES, pH 8.0, and 10 mM reduced
glutathione with 200 units TEV protease at 4 C. After the addition of
NaCl (ﬁnal concentration: 300 mM), the liberated serpin moiety was
separated from the His-tag containing proteins (residual fusion pro-
tein, GST and TEV protease) by chromatography on a Protino Ni
2000 column, equilibrated in 50 mMHEPES, 0.15% Triton X-100, and
300 mM NaCl. The ﬂow-through containing the puriﬁed Spn4A-1 was
collected and stored at )80 C. The purity of the preparations was
assessed by staining with Coomassie blue after SDS–PAGE [21]. The
concentration of the puriﬁed proteins was determined by a standard
Bradford assay (Pierce).2.4. Generation and analysis of inhibitor/enzyme complexes
Puriﬁed fusion protein or TEV-liberated Spn4A-1 was incubated
with titrated human furin at a molar ratio of 8:1 at 25 C in 100 mM
HEPES, pH 7.5, containing 1 mM Ca2þ and 0.5% Triton X-100 (ki-
netic buﬀer). The reaction products were resolved by reducing SDS–
PAGE (10% gels) and analyzed by Western blotting [21]. Antibodies
were used at a dilution of 1:20 000 (anti-Spn4 antiserum) or 1:500 (anti-
furin antibody).
2.5. Scissile bond analysis
Puriﬁed Spn4A-1 (1.25 lg) was incubated in 50 mMHEPES, pH 7.5,
containing 1 mM CaCl2 for 2 h at 25 C in the absence or presence of
furin (0.1 lg). After addition of an equal volume of 0.5% TFA, the
samples were desalted with ZipTip C18 following the manufacturer’s
instructions (Millipore), applied to the MALDI target chip and mixed
with 1 ll matrix solution (10 mg/ml sinapic acid in acetonitrile/water
(30:70) containing 0.07% TFA). MALDI-TOF/MS spectra (acceler-
ating voltage: 25 kV) were recorded with a Voyager DE instrument
(PE Biosystems, Weiterstadt, Germany) equipped with an LSI nitro-
gen laser and a 1.2 m linear ﬂight tube.
2.6. Enzymatic assays and kinetic methods
Assays (100 ll) were conducted in 96-well microtiter plates at 30 C
in kinetic buﬀer using a FLUOstar/POLARstar galaxi spectrometer
(bmg labtechnologies). Cleavage of the ﬂuorogenic substrate
pERTKR-MCA was initiated with 1 unit of human furin and release
of 7-amino-4-methylcoumarin (AMC) was monitored at 460 nm (ex-
citation wavelength: 380 nm). The background resulting from spon-
taneous substrate hydrolysis was subtracted. By non-linear regression
(EnzFitter, Biosoft), a value of 20 2 lM was calculated for the
Michaelis constant (Km), using substrate concentrations between 0.3
and 200 lM.
The concentration of catalytically active furin was determined by
titrating with the active site-directed inhibitor dec–RVKR–cmk [22].
The enzyme (3 units) was incubated in kinetic buﬀer with the chlo-
romethylketone (0–67 nM) for 1 h at 30 C. After 10-fold dilution and
addition of pERTKR-MCA to 200 lM, the rate of substrate hydro-
lysis was measured and plotted versus the inhibitor concentration. A
regression line was ﬁtted to the initially linearly decreasing values of
residual enzyme activity. The concentration [E0] of active furin was
extrapolated from the intersection with the x-axis. Three units of the
titrated enzyme (0.011 pmol per unit) were incubated in the samemanner with increasing concentrations of Spn4A-1 (0–15 nM, as de-
termined with the Bradford assay).
Progress curves for furin inhibition at diﬀerent Spn4A-1 concen-
trations [I ] were recorded under pseudo ﬁrst-order conditions using
furin at a concentration of 0.11 nM and the substrate pERTKR-MCA
[S] at 200 lM. The data were ﬁtted to Eq. (1) for slow tight binding
inhibition with a steady state velocity of zero [23,24],
P ¼ v0
k0
ð1 ek0 tÞ þ b ð1Þ
where P is the ﬂuorescence; m0, the initial velocity; t, the time; k0, the
apparent ﬁrst order rate constant; and b, the ﬂuorescence at time t ¼ 0.
Non-linear regression (EnzFitter) provided k0 for each [I]. By plotting
k0 versus [I], kassoc was obtained from linear regression according to the
following equation [25]:
k0 ¼ kassocð1þ ½S=KmÞ  ½I  ð2Þ
2.7. Transfection of COS-7 cells and immunoﬂuorescence analysis
COS-7 cells were cultivated in DMEM containing 10% FCS. The
cells were transfected in 4-well Lab-Tek chamber slides (Nunc) with
Lipofectamine 2000 (Invitrogen) following the supplier’s instruc-
tions. After 24 h, cells were rinsed with PBS, ﬁxed with )20 C cold
methanol and treated with blocking/washing solution (3% (w/v) BSA
in PBS). For immunostaining, the anti-Spn4 rabbit antiserum (Section
2.1) and a FITC labeled anti-rabbit antibody (Sigma, F1262) were
used. The ER marker, protein disulﬁde isomerase (PDI), was localized
using a monoclonal mouse antibody (Stressgen, SPA-891) and a Cy3-
labeled anti-mouse antibody (Jackson ImmunoResearch Labs, 715-
165-150). All antibodies were diluted 100-fold in blocking/washing
solution. The cells were mounted with Mowiol 4.88 medium (Calbio-
chem). Fluorescence was examined with an Olympus IX81 epiﬂuo-
rescence microscope (40 objective) equipped with a Hamamatsu
C8484-05G camera. Color and intensity adjustments of the pictures
and the overlay were performed with Adobe Photoshop, version 7.3. Results
3.1. Recombinant expression
To produce Spn4A-1 in suﬃcient amounts and purity, we
constructed an expression plasmid coding for a fusion protein
consisting of isoform Spn4A connected via a TEV protease
cleavage site sequence to the N-terminal GST (containing a
His-tag at its N-terminal end). The chimera was isolated from
the bacterial cytosol and puriﬁed on Glutathione Sepharose
4B. After cleavage with TEV protease, all His-tagged compo-
nents (residual fusion protein, cleaved GST and TEV protease)
were removed by metal aﬃnity chromatography. Analysis by
SDS–PAGE (Fig. 1) showed that highly puriﬁed Spn4A-1 had
been obtained, which was expected to include two additional
amino acids (Gly-Ala) at its N-terminus as a result of TEV
protease cleavage.
3.2. Complex formation with furin
Incubation of Spn4A-1 – either in the fused or in TEV
protease liberated form – with human furin resulted in the
formation of SDS stable complexes (Fig. 2) as demonstrated
by Western blotting, using antibodies directed against the fu-
sion protein or against human furin, respectively. The appar-
ent sizes of the complexes were 135 and 115 kDa,
respectively, depending on whether the fused serpin or TEV
cleaved Spn4A-1 was used. Enzyme/inhibitor complexes were
detected after only 20 s of incubation (not shown). A fraction
of the serpin migrated at an increased rate (39 kDa) after in-
cubation with furin, in accordance with the branched pathway
mechanism of serpins [3]. The 53 kDa band corresponding to
free furin did not appear when denaturation was performed at
Fig. 1. Isolation of Spn4A-1. GST-Spn4A-1 was puriﬁed from bacte-
rial extracts via Glutathione Sepharose 4B (lane 1) and treated with
TEV protease (lane 2). His-tagged components were removed by metal
aﬃnity chromatography (lane 3). Proteins were stained with Coo-
massie brilliant blue after SDS–PAGE (10% gels). The positions of the
size markers are given on the right.
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complex dissociates only under harsh conditions.
3.3. Identiﬁcation of the scissile bond
Spn4A contains the sequence RRKRA within its RSL (po-
sitions 371–375) that closely resembles the furin recognition/
cleavage site RXR/KR#. In order to identify the actual P1–P10
positions of Spn4A-1, the inhibitor was co-incubated with
furin followed by MALDI-TOF/MS analysis of the reaction
products. Cleavage of Spn4A-1 (calculated average mass:Fig. 2. Complex formation between Spn4A-1 and furin. Fused or TEV-cleave
and boiled for 4 min in reducing SDS-PAGE buﬀer. After electrophoresis (10
antibodies directed against GST-Spn4 (A) or human furin (B). Lane 1, furin
Spn4A-1; and lane 5, GST-Spn4A-1 incubated with furin. The furin-cleaved
positions of the size markers are given on the right side of each panel.44255.6 Da) at the furin consensus sequence was expected to
generate fragments of 38454.1 and 5819.5 Da, respectively.
Fig. 3 shows that furin cleavage of Spn4A-1 resulted in the
appearance of a fragment at m=z ¼ 38422:5 and a set of frag-
ments at m=z ¼ 5000–6000 that included a fragment at
m=z ¼ 5819:5 as most intense signal, in accordance with the
furin cleavage site. No such signals were observed with un-
treated Spn4A-1 (control), indicating that these signals were
not due to unspeciﬁc proteolysis. The data thus show that
Arg–Ala constitute positions P1–P1
0
for the interaction with
furin. Moreover, alternative basic amino acids are not used as
P1 residues (expected average masses: 5975.7; 6103.9; and
6260.1 Da).
3.4. Inhibition of furin
For determining the stoichiometry of inhibition (SI), furin
was titrated with the active site directed inhibitor dec–RVKR–
cmk and Spn4A-1, respectively. We calculated an SI value of
about 3.5 and a 4.5-fold excess of the serpin was found to be
suﬃcient to abolish furin activity completely. To determine the
apparent association rate constant, the enzyme was incubated
with increasing amounts of puriﬁed Spn4A-1 using an at least
10-fold excess of inhibitor to meet pseudo-ﬁrst order condi-
tions and progress curves reﬂecting the interaction between
furin and the serpin were recorded (Fig. 4). The ﬂuorescence
reached a limit value and there was no return of enzyme ac-
tivity for at least 24 h of incubation (not shown). Using non-
linear regression analysis, an apparent kassoc of (5.5 0.5) 106
M1 s1 was calculated.
3.5. Subcellular localization of Spn4A in transfected COS-7
cells
To investigate the potential role of Spn4A as a cellular
regulator of furin-like enzymes in the ER and secretory routes,
COS-7 cells were transfected with a plasmid coding for Spn4A
containing the genuine signal peptide and the C-terminald Spn4A-1 was incubated for 2 min with furin in the presence of Ca2þ
% gels), the reaction products were analyzed by Western blotting, using
; lane 2, Spn4A-1; lane 3, Spn4A-1 incubated with furin; lane 4, GST-
forms of GST-Spn4A-1 and Spn4A-1 are marked by an asterisk. The
Fig. 3. Identiﬁcation of the scissile bond. Puriﬁed Spn4A-1 (calculated
average mass: 44255.6 Da) was incubated with human furin followed
by MALDI-TOF/MS. Consistent with the expected cleavage site, sig-
nals at m=z ¼ 38422:5 (A) and 5819.5 (C) are observed that are not
present in the untreated control (B, D).
Fig. 4. Progress curves for the inhibition of human furin (0.11 nM) by
Spn4A-1 (0–4.0 nM). The inset shows that k0 linearly depends on the
Spn4A-1 concentration. The apparent constant kassoc was derived from
the slope of the regression line (Section 2.6).
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nostaining analysis was performed. The established ER marker
PDI [26] was detected in all cells with a characteristic peri-
nuclear staining pattern (Fig. 5A). In contrast, only cells
transfected with the Spn4A expression plasmid (Fig. 5B)
showed a marked FITC ﬂuorescence that did neither occur in
cells transfected with the empty vector nor using the secondary
antibody alone or in combination with a rabbit control serum
(not shown). The FITC ﬂuorescence showed the same sub-
cellular distribution as that of Cy3, demonstrating co-locali-
zation of Spn4A and PDI (Fig. 5C). The experiment thus
indicates that the genuine N-terminal signal peptide and the
HDEL sequence of Spn4A mediate import and retention of the
fruit ﬂy serpin in the ER of mammalian cells.4. Discussion
The present communication demonstrates that a re-
combinant serpin Spn4A variant, that diﬀers solely by an
N-terminal extension of two amino acids from the genuine
sequence, forms SDS-stable complexes with human furin. The
inhibitor is cleaved C-terminally to the sequence RRKR, in
agreement with the recognition/cleavage site of the prohor-
mone convertase. The co-localization of Spn4A with the ER
marker PDI in transfected COS-7 cells and the kinetic pa-
rameters of Spn4A/furin interaction suggest that Spn4A may
be a physiological regulator of furin and/or related targets.
The bacterially expressed serpin inhibits furin with a high
apparent kassoc of 5.5 106 M1 s1. Correcting for the SI of
the reaction [3], an overall kassoc of 1.9 107 M1 s1 was
extrapolated from these data, a value that is comparable to
that determined by Richer et al. [27] for N-terminally His-
FLAG-tagged Spn4A (kassoc ¼ 3:2 107 M1 s1, SI  1).
Using C-terminally His-tagged Spn4A extracted from soni-
cated bacteria, Osterwalder et al. [28] calculated an apparent
kassoc of 2.1 105 M1 s1 for inhibition of human furin (de-
termined at 22 C) and an eightfold molar excess of the in-
hibitor was necessary to achieve 65% reduction of the
enzyme’s amidolytic activity. These apparent diﬀerences could
be due to several diﬀerent factors, including (i) eﬀects exerted
by the varying positions and sequences of the tags used for the
expression constructs, (ii) the conditions employed for prep-
aration and storage of the recombinant serpin, (iii) the dif-
ferent enzyme/inhibitor ratios used for determining the kinetic
parameters and (iv) the strongly temperature-dependent par-
tition of Spn4A between the inhibitory and the substrate
pathway of serpins [27].
A few other serpins have been shown to inhibit furin. The
genetically engineered serpin a1-PDX, which contains the se-
quence RIPR within its RSL [15], inhibits furin with a kassoc of
1.5 106 M1 s1 [29] and for human protease inhibitor 8
(PI8), a kassoc value of 6.5 105 M1 s1 was determined [30].
In order to control furin at its cellular locations, inhibitors
must gain access to the secretory pathway. PI8 does not con-
tain the cleavable N-terminal signal peptide required for en-
tering the ER and histochemical investigations localize human
PI8 primarily within the nucleus [31] in contrast to the genet-
ically engineered a1-PDX that is predominantly found within
the trans-Golgi network [32]. The subcellular distribution of
Spn4A in transfected COS-7 cells suggests that the inhibitor
may represent the ﬁrst natural serpin that can be retrieved to
Fig. 5. Intracellular localization of Spn4A. COS-7 cells were transfected with an expression plasmid coding for Spn4A, including the genuine signal
peptide and the C-terminal HDEL sequence. Cells were ﬁxed and prepared for immunostaining as described in Section 2.7. (A) Cy3 immunoﬂu-
orescence of the ER marker PDI; (B) FITC ﬂuorescence of cells expressing Spn4A; (C) overlay of FITC- and Cy3 ﬂuorescence demonstrating co-
localization of SpnA and PDI.
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secretory routes of eukaryotic cells. In Drosophila melanogas-
ter, two genes coding for furin homologs have been identiﬁed
[33–35], which could be possible targets for Spn4A. Genetic
[28] and biochemical experiments [27] indicate that Spn4A may
control Amontillado, the Drosophila homolog of the mam-
malian prohormone convertase PC2 [36,37]. Further targets
could include subtilase-like enzymes from pathogens that in-
vade cells via the secretory pathway.
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